Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Global Confirmatory Study Evaluating the Efficacy and Safety of Quantum-Inspired Intervention (QII), a Novel Neurodevelopmental Intervention, for Improving Emotional Stability and Social Communication in Children With Autism Spectrum Disorder

NCT07898787 is registered in ClinicalTrials.gov with BlissBot, Inc as lead sponsor.

NCT NCT07898787 Not yet recruiting Not applicable 80 participants (estimated) Started 2027

Follow this trial by email Email me the PDF

Get the NCT07898787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started February 2027. Interventional study, 80 participants (estimated). Lead sponsor BlissBot, Inc. Primary measure: Clinical Global Impression-Improvement (CGI-I) Score for the Primary Intervention Target.

How it compares

547 similar trials: same condition (Autistic Disorder) and phase

Enrollment

This trial
80
Middle half
26 to 100
Median
50
Trials with a value
546

Months from start to completion

This trial
15
Middle half
12.9 to 46
Median
25
Trials with a value
545

Sites

This trial
Not reported
Middle half
1 to 1
Median
1
Trials with a value
514
Posted results or a linked paper 48% 261 of 547 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Global Confirmatory Study Evaluating the Efficacy and Safety of Quantum-Inspired Intervention (QII), a Novel Neurodevelopmental Intervention, for Improving Emotional Stability and Social Communication in Children With Autism Spectrum Disorder
Lead sponsor
BlissBot, Inc
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
May 31, 2028
Enrollment
80 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Autism Spectrum Disorder, Autistic Disorder

Registry terms: asd, autism spectrum disorder (asd

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
5 Years
Maximum age
17 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
BlissBot, Inc

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Quantum-Inspired Intervention (QII) Experimental Quantum-Inspired Intervention (QII)
Show registry wording

Participants receive the proprietary Quantum-Inspired Intervention (QII) protocol over a 3-month intervention period. Delivery is conducted entirely remotely by trained practitioners without requiring on-site visits or added labor burden for the family. Following caregiver intake, AI-enabled developmental profiling, and caregiver-confirmed Developmental Report alignment, standardized non-contact protocol sessions are administered. Participants continue their usual care throughout the study. Efficacy endpoints are assessed by blinded independent assessors at baseline and at the end of the 3-month intervention period.

Waitlist Control (Delayed QII) No intervention
Show registry wording

Participants complete the identical procedural workflow as the experimental arm, including caregiver intake, AI-enabled developmental profiling, and Developmental Report alignment, and continue their usual care, but do not receive the QII protocol during the 3-month intervention period. Efficacy endpoints are assessed by blinded independent assessors at the same time points. Following completion of the primary analysis, participants are offered the QII protocol, provided that no safety concerns have been identified by the Data Monitoring Committee (DMC).

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Clinical Global Impression-Improvement (CGI-I) Score for the Primary Intervention Target End of the 3-month QII intervention period
Show registry wording

CGI-I rated by a blinded independent clinician on a 7-point scale (1 = very much improved; 7 = very much worse), assessing improvement relative to baseline in the autism-related symptom or functional difficulty identified as the primary intervention target at baseline. Response is defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

Similar trials

Same condition (Autistic Disorder) and phase, most recent start first.